Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new tracer light up bone cancer tumors?

NCT ID NCT07774533

Diagnosis Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This trial tests whether a new radioactive tracer, called 68Ga-B7-H3 nanobody, can safely and effectively highlight osteosarcoma tumors on PET/CT scans. Participants with relapsed or refractory osteosarcoma will receive a single injection of the tracer, followed by imaging to see how well it binds to tumors and detects lesions. The study compares these images with standard scans and biopsy results to assess the tracer's potential for improving diagnosis and disease evaluation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
68Ga-labeled B7-H3 nanobody (a radioactive tracer for PET/CT imaging)
What this could lead to
If successful, this imaging approach could help doctors detect osteosarcoma lesions more accurately, guiding better treatment decisions.
What could go wrong
This is an early-phase, small study (16 participants), so results may not apply broadly. The tracer may not clearly highlight all tumors, and there is a small risk of side effects from the radioactive agent.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 16 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

10 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥10 years. * Histologically confirmed osteosarcoma. * Relapsed or refractory disease following failure of first- or second-line systemic therapy. * Ability to understand the study procedures and provide written informed consent (or assent with parental/legal guardian consent, where applicable). Exclusion Criteria: * Pregnant or breastfeeding. * Severe uncontrolled systemic disease or medical condition that, in the investigator's judgment, may interfere with study participation or image interpretation. * Unable to undergo PET/CT examination. * Any condition that, in the investigator's judgment, makes the participant unsuitable for enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteosarcoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteosarcoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Osteosarcoma Osteosarcoma, recurrent, refractory

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking University First Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100034, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.